

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FMC BIOPOLYMER AS	08/15/2006
RECEIVING PARTY DATA	
Name:	ALGIPHARMA HOLDING AS
Street Address:	Tomtegt. 36
City:	Drammen
State/Country:	NORWAY
Postal Code:	N-3012
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	7553656
Patent Number:	6121441
CORRESPONDENCE DATA	
Fax Number:	8664222625
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	610640.7800
Email:	bergert@pepperlaw.com
Correspondent Name:	Pepper Hamilton LLP
Address Line 1:	400 Berwyn Park, 899 Cassatt Road
Address Line 4:	Berwyn, PENNSYLVANIA 19312
NAME OF SUBMITTER:	Tonya M. Berger
Total Attachments: 3 source=FMC - AlgiP Hold Assignment#page1.tif source=FMC - AlgiP Hold Assignment#page2.tif source=FMC - AlgiP Hold Assignment#page3.tif	

OP \$80.00 7553656

ASSIGNMENT

WHEREAS, WE, FMC BIOPOLYMER AS, org. no. 980 859 525, a corporation organized under and pursuant to the laws of Norway, having its principal place of business at Tomtegt. 36, 3012 Drammen, Norway, (hereinafter FMC) is the owner of the entire right, title and interest in and to the patents and the applications for patents listed in Schedule A, attached hereto and made a part hereof, of the inventions disclosed and claimed therein, and of the priority rights relating thereto, and has the unrestricted right to sell, assign and transfer such patents and applications;

WHEREAS, FMC and AlgiPharma Holding AS have reached agreement related to related to transfer of the rights to patents listed in Schedule A and this Assignment is being filed pursuant to such agreements, and

NOW, THEREFORE, be it known that for valuable consideration, the receipt whereof is hereby acknowledged, FMC sells, assigns, and transfers its entire right, title and interest in said patents and patent applications and all continuations, divisionals, continuations-in-part, reissues, reexaminations, foreign counterparts, etc., thereof to ALGIPHARMA HOLDING AS (at present Kula AS), org. no. 964 911 444, a company duly incorporated and existing under the laws of Norway whose registered office is at Tomtegt. 36, N-3012 Drammen, Norway (hereinafter ASSIGNEE).

IT IS AGREED that FMC shall be legally bound, upon request and at the expense of the ASSIGNEE or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practice of said inventions or patents and patent applications, to testify in any legal proceeding relating thereto, to execute all instruments and do such other acts as may be necessary and proper to patent the inventions in the name of the ASSIGNEE and to execute all instruments proper to carry out the intent of this instrument.


IT IS AGREED that FMC retains an exclusive license in all areas outside the fields of treatment of human and animal respiratory diseases and symptoms thereof; and treatment of human and animal chronic surface wounds. AlgiPharma Holding AS has the rights of first right of refusal in licensing these rights.

FMC hereby warrants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

IN TESTIMONY WHEREOF, this Assignment is executed on the day indicated below:

FMC BIOPOLYMER AS

ARVE DESSEN
Printed Name


Signature

MANAGING DIRECTOR
Title

Drammen 15.08.2006
Date

Schedule A

FMC Docket No.	Patent No.	Title/Granted/Priority Date/Expiration Date
60198	US 5,169,840	Di-equatorially Bound Beta-1,4 Polyuronates and Use of Same for Cytokine Stimulation Granted; USA, France, Great Britain, Germany, Italy, Japan Priority date; 27 March 1991, Expiration date; 27 March 2011/2012
60204	US 6,087,342	Substrate Materials with Bound Cytokine-Stimulating Polysaccharides or Bacterial Nucleic Acids Granted; USA, Great Britain. Filed; EPC (Europe), Hong Kong, Japan Priority date; 16 May 2017/15 May 2018
60263	WO04011628	New Mutant Strains of Pseudomonas Fluorescens and Variants Thereof, Methods of Their Production, and Uses Thereof in Alginate Production Filed; Norway, PCT (International Patent Application). Priority date; 26 July 2002
60200	US 5,939,289	DNA Compounds Comprising Sequences Encoding Mannuronan C-5-Epimerase Granted; USA, Denmark, France, Great Britain, Germany, Italy, South Korea, Netherlands, New Zealand. Filed; Canada, Finland, Japan, Norway Priority date; 08 October 1992, Expiration date; 08 October 2013/17 August 2016
60199	US 5,166,137	Guluronic Acid Polymers and Use of Same for Inhibition of Cytokine Production Granted; USA, France, Great Britain, Germany, Italy. Filed; Japan Priority date; 27 March 1991, Expiration date; 27 March 2011/24 March 2012
60202	US 6,121,441	Procedure for Producing Uronic Acid Blocks from Alginates Granted; USA, Australia, China, France, Great Britain, Germany, Norway. Filed; Brazil, Canada, Japan Priority date; 9 May 1997, Expiration date; 8 May 2018
60469	60/762194 (patent application no)	Skin collagen protection with alginate in wound care US provisional patent application filed January 25 2006 (no claims specified). Full patent application with set of claims to be drafted within January 25 2007.

Kula AS has up till now had rights in FMC Docket no.: 60198, 60200, 60199 and 60204. All Kula AS rights in FMC Docket no.: 60198, 60200, 60199 and 60204 are being waived upon today's creation of AlgiPharma Holding AS.